ETHIC Act
- Sponsor
- Sen. Welch, Peter [D-VT]
- Committees
- Judiciary Committee (primary)
- Last action
- Jul 15, 2025
Bottom line
The ETHIC Act seeks to streamline patent litigation for generic drugs and biosimilars by limiting the number of related patents that can be asserted in a single infringement lawsuit, aiming to foster competition and lower drug prices.
What it actually does
This bill amends federal patent law to limit the number of patents that can be asserted in an infringement action against generic drug manufacturers or biosimilar developers. Specifically, it restricts patent holders to asserting only one patent per 'Patent Group' in such lawsuits, where a Patent Group consists of commonly owned patents linked by 'obviousness-type double patenting' disclaimers. This aims to reduce the practice of 'patent thickets' which can delay market entry for cheaper drug alternatives.
Proponents argue
Proponents argue that the bill will combat abusive patenting practices, often referred to as 'patent thickets,' where pharmaceutical companies amass numerous patents around a single product to block generic and biosimilar competition. They contend this will lower drug prices, increase patient access to affordable medications, and promote innovation by reducing the legal burden on challengers.
Opponents contend
Opponents, likely pharmaceutical innovators, would argue that this bill undermines intellectual property rights, disincentivizes research and development by weakening patent protections, and could lead to less innovation in new drug discovery. They might also claim it unfairly targets complex innovations that legitimately require multiple patents for comprehensive protection.
The bill text is very short and can be read quickly, but understanding its full implications requires familiarity with patent law and pharmaceutical regulatory processes.
Section 2(a), amending Section 271(e) of title 35, United States Code.
Restriction on Patent Assertions in Drug/Biologic Infringement Cases
This provision limits a patent holder to asserting only one patent per 'Patent Group' when suing a generic drug manufacturer or biosimilar developer for infringement. A 'Patent Group' is defined as two or more commonly owned patents or applications that are linked by 'obviousness-type double patenting' disclaimers. This means if a company has multiple patents that are very similar and only granted because they disclaimed extending the patent term, they can only assert one of those in a lawsuit.
Supporters argue
Supporters argue this provision directly targets 'patent thickets,' which are seen as a tactic to stifle competition. By limiting the number of patents that can be asserted, it reduces the complexity and cost of litigation for generic and biosimilar companies, thereby accelerating the availability of more affordable medicines.
Critics contend
Opponents would contend that this provision weakens legitimate patent protections, especially for complex pharmaceutical innovations that may require multiple, albeit related, patents to fully cover the invention. They might argue it could lead to under-protection of intellectual property, discouraging investment in R&D for new drugs.
Tradeoffs
The bill seeks to balance the protection of intellectual property rights for innovators with the public interest in affordable access to medicines and fostering competition. The tension lies in determining the appropriate scope of patent protection without enabling anti-competitive practices.
Section 2(b)
Effective Date for New Patent Assertion Limits
This subsection specifies that the new limits on patent assertions will only apply to applications for generic drugs or biosimilars submitted on or after the date the Act is enacted. This means it does not retroactively affect ongoing litigation or applications filed before the bill becomes law.
Defines 'Patent Group' as two or more commonly owned patents or applications that are identified on or subject to disclaimers under section 253 to obviate 'obviousness-type double patenting' of another commonly owned patent.
Section 2(a), amending 35 U.S.C. 271(e)(7)(D).
Why it matters:This is standard legislative practice for amending existing statutes; it assumes familiarity with the underlying legal framework. It is not intentionally evasive but requires legal expertise.
Case for: Supporters would argue that this precise legal definition targets a specific, well-understood patenting strategy used to extend protection beyond the scope of a single invention, ensuring the bill is narrowly tailored to address the problem of patent thickets without broadly undermining patent rights.
Case against: Critics might argue that the technical nature of the definition makes it difficult for non-specialists to understand the full scope of the bill's impact, potentially obscuring its reach or unintended consequences.
Estimated impact: This definition is central to the bill's entire mechanism, directly determining which patents are grouped together and thus limited in assertion. Its impact is fundamental to the bill's effectiveness in addressing patent thickets.